explore -WSS

explore

author：fashion 2025-09-05 18:31:59 - browse：18

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Why health records don't always know when patients are dead

leisure time

WSS

How to make AI work for medicine

Grail spinoff by Illumina should end disastrous merger attempt

SNAP should offer more nutrition education

Albert Bourla of Pfizer: worst biopharma CEO of 2023

How to keep neuroscience’s past racism from being its future

HCA sued by state AG for quality issues at Mission Health

entertainment

explore

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NYU Langone launches private ChatGPT for its health care data

George Santos makes 1st court appearance after pleading not guilty to 13 counts

SNAP should offer more nutrition education

Bright Health sells Medicare Advantage business to Molina

Radiation, mainstay of cancer treatment, begins a fade

Peter Hotez and the public health issue of online harassment

Grail spinoff by Illumina should end disastrous merger attempt

Medical records are filled with copy

How to keep neuroscience’s past racism from being its future

focus

Apellis safety probe of eye disease drug centers on injection needle

Virtual care provider acquires bankrupt Pear's prescription apps

Three trends to watch in biotech in 2024

Study finds new variant for Parkinson’s in African populations

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Complete sequence of Y chromosome published for first time

leisure time

leisure time

knowledge

entertainment